Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.35 | N/A | -12.90% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.35 | N/A | -12.90% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern over current performance and indicated the need for a revised approach to meet future goals.
Management acknowledged challenges in achieving profitability.
They emphasized the need for strategic adjustments moving forward.
Veracyte's earnings report indicates ongoing challenges, particularly with profitability, as reflected in the EPS miss. The stock's 1.6% decline suggests investor concern over the company's ability to navigate these issues. Without guidance, uncertainty remains about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CREDICORP LTD
Aug 10, 2015